Pilocarpine Prodrugs II. Synthesis, Stability, Bioconversion, and Physicochemical Properties of Sequentially Labile Pilocarpine Acid Diesters

doi:10.1002/jps.2600750811

Journal of Pharmaceutical Sciences

Volume 75, Issue 8, August 1986, Pages 775-783

https://doi.org/10.1002/jps.2600750811 Get rights and content

Abstract

Various novel diesters of pilocarpic acid were synthesized and evaluated as prodrug forms for pilocarpine with the aim of improving the ocular delivery characteristics of the drug. The pilocarpic acid monoesters previously studied cyclized spontaneously to pilocarpine in aqueous solution and although they showed enhanced corneal permeability when compared with pilocarpine these monoesters suffered from poor solution stability. The present study shows that this problem can be totally overcome by blocking the free hydroxyl group in the monoesters. Diesters of pilocarpic acid were obtained by esterification of this group. Such compounds were found to possess a high stability in aqueous solution (shelf lives of more than 5 years at 20°C were estimated) but at the same time were readily converted to pilocarpine under conditions simulating those occurring in vivo through a sequential process involving enzymatic hydrolysis of the O-acyl bond followed by spontaneous lactonization of the intermediate pilocarpic acid monoester. Rate data are given for the conversion of the diesters in human plasma and in various rabbit eye homogenates. The pH–solubility profile was derived for a diester and lipophilicity parameters were determined for the compounds. All diesters were markedly more lipophilic than pilocarpine and the corresponding pilocarpic acid monoesters. The results suggest that pilocarpic acid diesters may be potentially useful pilocarpine prodrugs as they combine a high solution stability with an adequate rate of conversion to pilocarpine under in vivo conditions.

References and Notes (24)

H. Bundgaard et al.
Int. J. Pharm.
(1982)
The iris and ciliary body were removed and used together and will hereafter be referred to as the iris–ciliary...
C. Hansch et al.
Substituent Constants for Correlation Analysis in Chemistry and Biology
(1979)
M. Dixon et al.
Enzymes
(1979)
M.A. Nunes et al.
J. Pharm. Sci.
(1974)
G.A. Neville et al.
Con. J. Chem.
(1976)
H. Bundgaard et al.
J. Pharm. Sci.
(1986)
H. Bundgaard et al.
J. Med. Chem.
(1985)
H. Bundgaard et al.
Eur. Patent Appl. 106 541
(1984)
Chem. Abstr.
(1985)
A. Noordam et al.
J. Pharm. Sci.
(1981)

V.H.L. Lee et al.

Curr. Eye Res.

(1985)

A. Hussain et al.

J. Pharm. Sci.

(1976)

Cited by (72)

Prodrugs - Current development and applications in ocular drug delivery
2021, Journal of Drug Delivery Science and Technology
Citation Excerpt :
Pilocarpine is a cholinergic agent commonly used to treat or manage glaucoma. It has a lower absorption in the cornea, therefore it cannot penetrate into the ocular tissues as its log P is −0.15 [63]. Design and synthesis of pilocarpine prodrug (Fig. 5) in ocular drug delivery has proven beneficial and improves the corneal absorption of the parent drug.
The clinical therapeutic regimen for disease treatment of the anterior portion of an eye involves the use of eye drops with mediocre success due to rapid eye drainage and poor bioavailability. These conventional delivery mechanisms do not penetrate the posterior portion of the eye and are ineffective in treating posterior segment diseases like, retinitis pigmentosa, age related macular degeneration, diabetic retinopathies, and glaucoma. This has led to augmented research in development of drug delivery alternatives for subconjunctival and periocular administration, drug that targets bloodstream to the retinal pigment epithelium or choroidal vasculature, and prodrugs. Ocular pharmacokinetics is a highly studied area to develop strategies that circumvent the associated barriers in ocular drug delivery and achieve better clinical outcomes. The viable strategies for enhancing ocular bioavailability involves physical methods like formulating drugs as solutions, suspensions, gels and chemical methods like development of prodrugs and soft drugs. The application of prodrug design offers the advantages of higher ocular tissue permeability, superior bioavailability, transporter targeting, site specificity and enhanced aqueous solubility with minimal disruption of the barriers to ocular diffusion. This review focuses mainly on recent progress in prodrug strategies like lipid-based prodrugs, transporter targeted prodrugs, hydrophilic and polymeric prodrugs developed to improve delivery to the otherwise resilient eye. The success of conventional and emerging prodrug design strategies depends on many factors like chemical structure of the drug, ease of prodrug synthesis, capacity of targeted transporters and in vivo metabolic activation attributes. Inspite of the associated challenges, prodrugs have witnessed reasonable market success and the new prodrug design strategies are envisaged to enable delivery of conventional drugs, antibodies, oligonucleotides, genes, and growth factors to the eye offering patient compliant, safer and superior treatment of posterior segment diseases.
Ocular prodrugs: Attributes and challenges
2021, Asian Journal of Pharmaceutical Sciences
Citation Excerpt :
It exhibits low level of absorption in the corneal site due to which it cannot penetrate into ocular tissues to exhibit its effect. Its log P value is −0.15 [102]. So the answer to the above problem was in the synthesis of pilocarpine prodrug (Fig. 10) that would improve the corneal absorption of parent drug and prove beneficial in ocular drug delivery.
Ocular drug delivery is one of the most attention-grabbing and challenging endeavors among the numerous existing drug delivery systems. From a drug delivery point of view, eye is an intricate organ to investigate and explore. In spite of many limitations, advancements have been made with the intention of improving the residence time or permeation of the drug in the ocular region. Poor bioavailability of topically administered drugs is the major issue pertaining to ocular drug delivery. Several efforts have been made towards improving precorneal residence time and corneal penetration, e.g. iontophoresis, prodrugs and ion-pairing, etc. Prodrug approach (chemical approach) has been explored by the formulation scientists to optimize the physicochemical and biochemical properties of drug molecules for improving ocular bioavailability. Formulation of ocular prodrugs is a challenging task as they should exhibit optimum chemical stability as well as enzymatic liability so that they are converted into parent drug after administration at the desired pace. This review will encompass the concept of derivatization and recent academic and industrial advancements in the field of ocular prodrugs. The progression in prodrug designing holds a potential future for ophthalmic drug delivery.
Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery
2013, Asian Journal of Pharmaceutical Sciences
Citation Excerpt :
Although some lipophilic prodrugs present a promising ocular absorption, their highly lipophilic nature leads them to be difficult to dissolve in an aqueous medium, and raises a challenge in drug delivery in the form of eyedrops, in which form more than 90% of marketed ophthalmic formulations are developed. Such situations are exemplified by O-palmitoyl timolol [54] and pilocarpic acid diesters [53]. In the case of O-palmitoyl timolol, the prodrugs were administered in rabbits as a dispersion, because of low aqueous solubility, which may produce poor patient compliance and hinder their further use clinically.
Numerous systems have been designed during the past three decades to improve bioavailability of ophthalmic drug delivery, including: ocular prodrugs and nanotechnology-based drug delivery system. The former can improve the efficacy of ocular drug via enhancing corneal penetration of ocular drugs, prolonging their duration of action and/or reducing the systemic side-effects, unfortunately, some characteristics of the prodrugs, such as poorly aqueous stability, poorly aqueous solubility and severe eye irritation probably, limit their clinical practice and cannot be ignored. As we all know, nanotechnology for ocular drug delivery can carry poorly soluble drugs, protect the encapsulated molecules from hydrolysis, control the rate of drug delivery and prolong the precorneal retention of drugs. All of these merits may solve the problems in the utilization of ocular prodrugs and increase the bioavailability of ocular drug delivery. By reviewing recent advances of prodrugs and nanostructures in ocular drug delivery, this paper focus specifically on the promising prospects of nanocarriers overcoming the drawbacks of prodrugs for ophthalmic drug delivery by precorneal routes.
QSAR models for predicting enzymatic hydrolysis of new chemical entities in 'soft-drug' design
2009, Bioorganic and Medicinal Chemistry
The work described here is aimed at developing QSAR models capable of predicting in vitro human plasma lability/stability. They were built based on a dataset comprising about 200 known compounds. 3D structures of the molecules were drawn, optimized and submitted to the calculation of molecular descriptors that enabled selecting different TR/TS set pairs, subsequently exploited to develop QSAR models. Several ‘machine learning’ algorithms were explored in order to obtain suitable classification models, which were then validated on the relevant TS sets. Moreover the predictive ability of the best performing models was assessed on a Prediction set (PS) comprising about 40 molecules, not strictly related, from a structural point of view, to the initial dataset, but (obviously) comprised within the validity domain of the QSAR models obtained. The study allowed selecting predictive models enabling the classification of New Chemical Entities with regard to hydrolysis rate, that may be exploited for soft-drug design.
Designing Prodrugs and Bioprecursors
2008, The Practice of Medicinal Chemistry
The bioavailability of molecules exclusively screened through in vitro assays can be low. In vivo administration is limited to the parenteral route, and their clinical usefulness is thus restricted. Bioprecursors do not imply a temporary linkage between the active principle and a carrier group, but result from a molecular modification of the active principle itself. This modification generates a new compound, which is a substrate for metabolizing enzymes, leading to a metabolite that is the expected active principle. This approach exemplifies the active metabolite concept in a provisional way. Carrier prodrugs result from a temporary linkage of the active molecule with a transport moiety that is frequently of lipophilic nature. Bioactive compounds and drugs usually bear a limited number of polar functional groups suitable for carrier prodrug synthesis. Among these, the most frequent are the alcoholic and the phenolic hydroxyls, the amino group, and the carboxylic function. The aim is to illustrate how such groups can be used to prepare carrier prodrugs with improved pharmacokinetic properties. In the future it would be preferable to distinguish the carrier prodrug and the bioprecursor approaches. The design of bioprecursors, which represents a creative application of the active metabolite concept in the forward-looking way, seems a priori more adequate for CNS delivery, but its clinical usefulness still needs to be proven.
Conversion of cyclosporine A prodrugs in human tears vs rabbits tears
2005, European Journal of Pharmaceutics and Biopharmaceutics
The aim of this study was to evaluate the rate and mechanism of conversion of two water-soluble prodrugs of cyclosporine A (CsA) intended for topical delivery to the eye. The new molecules were designed according to the double prodrug concept: a solubilizing moiety was grafted onto CsA via an ester function, which could be hydrolysed via a two-step process (enzymatic and chemical). Prodrug solutions were prepared extemporaneously in an isotonic and neutral aqueous medium compatible with ophthalmic use. The rates of conversion into the parent molecule were determined by incubating the prodrugs in fresh rabbit or human tears or in a phosphate buffer solution (PBS) at pH 7.4. Both prodrugs were converted into CsA within the first minute in the presence of rabbit tears with rate constants of k=5.9×10⁻³ min⁻¹ and k=3.8×10⁻³ min⁻¹, respectively, for UNIL088 and UNIL089, whereas chemical conversion in PBS was negligible (k=0.5×10⁻³ min⁻¹ for both molecules). Incubation of UNIL088 in human tears showed a significantly high conversion rate. It is concluded that the developed double prodrugs underwent a bioconversion in physiological media and thus represent promising candidates for topical delivery of CsA to the eye.

View all citing articles on Scopus

^†: Deceased.

View full text

ArticlesPilocarpine Prodrugs II. Synthesis, Stability, Bioconversion, and Physicochemical Properties of Sequentially Labile Pilocarpine Acid Diesters

Abstract

Int. J. Pharm.

J. Pharm. Sci.

Con. J. Chem.

J. Pharm. Sci.

J. Med. Chem.

Eur. Patent Appl. 106 541

Chem. Abstr.

J. Pharm. Sci.

Curr. Eye Res.

J. Pharm. Sci.

Articles
Pilocarpine Prodrugs II. Synthesis, Stability, Bioconversion, and Physicochemical Properties of Sequentially Labile Pilocarpine Acid Diesters